Pan-Cancer Analysis Identifies YKT6 as a Prognostic and Immunotherapy Biomarker, with an Emphasis on Cervical Cancer

• DOI: 10.2147/ott.s491310
• Publication Date: 2025-01-22T07:15:12Z
• Authors: Jiamin Liu; Qiang Zhang; Ling He; Huangyu Hu; Yixuan Wang; Ping Xie
• Keywords: Cancer Immunotherapy

Background: Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-mediated membrane fusion is crucial for autophagy, making YKT6, a key modulator of cell fusion, potential target cancer therapy.However, its oncogenic role across different cancers remains unclear.This study was to investigate the prognostic value and immunological functions including cervical squamous carcinoma endocervical adenocarcinoma (CESC).Methods: Multiple bioinformatics databases, The Cancer Genome Atlas (TCGA), Cell Line Encyclopedia (CCLE), Genotype-Tissue Expression (GTEx) were used correlation YKT6 expression pattern with pathological stage survival rate cancers.Furthermore, ImmuCellAI, UCSC Xena platform, ESTIMATE algorithm subsequently utilized explore relationship between expression, tumor microenvironment, immune infiltration.Profiling gene mutation amplification, methylation, copy number alteration (CNA) performed on basis TCGA database.Moreover, q-PCR, TMA staining, siRNA assays validate cancer-promoting in CESCs.Results: Our results reveal that immunity biomarker.Elevated correlated poor overall (OS) disease-free (DFS).Distinct mutation, CNA patterns found certain types cancers.The tumor-infiltrating cells verified by analyzing StromalScore, ESTIMATEScore, ImmuneScore, purity.In vitro analysis confirmed highly expressed advanced-grade CESCs knockdown inhibited proliferation cells. Conclusion:The SNARE serves as biomarker candidate oncogene actionable mutations.Moreover, has be indicator CESCs.Targeting could enhance autophagy regulation improve therapeutic strategies personalized treatment.